Summary: The Centers for Medicare & Medicaid Services modified its prostate cancer screening tests coverage policy, effective May 15, 2026. Here's what billing teams need to know before that date.
CMS prostate cancer screening coverage has always been a pressure point for urology and primary care billing teams. This modification updates the rules governing what Medicare covers, who qualifies, and how claims must be supported. The policy does not list specific CPT or HCPCS codes in the available data — we'll address that directly below — but the coverage criteria and medical necessity requirements are the real story here.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Prostate Cancer Screening Tests |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Urology, Primary Care, Internal Medicine, Hematology/Oncology, Preventive Medicine |
| Key Action | Review documentation requirements and age/frequency criteria before May 15, 2026 |
CMS Prostate Cancer Screening Coverage Criteria and Medical Necessity Requirements 2026
The CMS prostate cancer screening coverage policy governs Medicare reimbursement for screening tests in male beneficiaries. Under long-standing Medicare statute, prostate cancer screening is a covered preventive benefit — but coverage is tightly tied to beneficiary age, frequency limits, and the specific test type. This modification may tighten or clarify those criteria.
Medicare has historically covered two categories of prostate cancer screening: the digital rectal exam (DRE) and the prostate-specific antigen (PSA) test. Both carry frequency restrictions. PSA testing has been covered annually for male Medicare beneficiaries age 50 and older. The digital rectal exam has been covered annually for male beneficiaries age 40 and older.
Medical necessity documentation is the first place claims fail here. CMS requires that the ordering provider document the clinical basis for the screening — not just a checkbox order. If your practice relies on standing orders or templated notes for annual PSA billing, this modification is a reason to audit that workflow before May 15, 2026.
Prior authorization is not typically required for covered prostate cancer screening under Medicare. But that doesn't mean prior auth pressure is absent. Medicare Advantage plans operating under CMS rules can impose their own prior authorization requirements — and many do. If your patient mix includes Medicare Advantage beneficiaries, verify plan-level requirements separately.
Frequency Limits and Age Thresholds
Age and frequency criteria are where most prostate cancer screening billing problems originate. CMS coverage policy is specific: one PSA test per 12-month period for male beneficiaries age 50 and older. Billing a second PSA within the same 12-month window without a diagnostic indication — not just a screening indication — is a straight path to claim denial.
The digital rectal exam carries similar frequency logic: once per 12-month period for male beneficiaries age 40 and older. When DRE and PSA are billed together at the same encounter, both must be individually supported in the documentation.
Providers who bill PSA for beneficiaries under age 50 under a screening indication will get denied. If there's a clinical reason — family history, symptoms, prior abnormal result — the claim shifts from screening to diagnostic. The code selection, modifier use, and documentation requirements all change at that point.
CMS Prostate Cancer Screening Exclusions and Non-Covered Indications
Not every PSA or DRE claim is a covered screening claim. CMS draws a clear line between screening and diagnostic services, and the billing implications are different on each side of that line.
Screening claims billed for beneficiaries outside the age thresholds are not covered. A PSA billed as a screening test for a 47-year-old Medicare beneficiary fails on eligibility, period. The clinical rationale may be sound. The coverage policy doesn't care.
Repeat screening within the 12-month frequency window is also not covered under the screening benefit. If a provider orders a follow-up PSA three months after an initial screening result — even for clinical reasons — that follow-up claim needs a diagnostic code, not a screening code. Billing it as screening is a documentation and coding error, not just a payer disagreement.
Prostate cancer screening under this coverage policy is a male benefit. Claims submitted for female beneficiaries under a prostate screening indication will deny. That sounds obvious, but it surfaces in practice when demographic data is wrong in the EHR.
Coverage Indications at a Glance
The available policy data does not include a granular indication-by-indication breakdown. Based on CMS's established coverage framework for prostate cancer screening, the table below reflects what Medicare covers and what it doesn't under this policy.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Annual PSA test, male beneficiary age 50+ | Covered | PSA/CPT codes not listed in policy data | Once per 12-month period; screening indication required |
| Annual digital rectal exam, male beneficiary age 40+ | Covered | DRE/CPT codes not listed in policy data | Once per 12-month period |
| PSA test, male beneficiary under age 50 (screening indication) | Not Covered | N/A | Does not meet age threshold for screening benefit |
| Repeat PSA within 12-month window (screening indication) | Not Covered | N/A | Frequency limit exceeded; diagnostic coding may apply |
| PSA or DRE billed as screening for female beneficiary | Not Covered | N/A | Eligibility failure |
| PSA with diagnostic indication (abnormal result, symptoms, family history) | Covered (diagnostic — different benefit) | Codes not listed in policy data | Different coverage rules apply; document clinical basis |
Note: The policy data provided does not list specific CPT or HCPCS codes. See the Affected Codes section below for detail on that gap.
CMS Prostate Cancer Screening Billing Guidelines and Action Items 2026
Here's what your billing and coding team should do before May 15, 2026.
| # | Action Item |
|---|---|
| 1 | Audit your charge capture for PSA and DRE frequency compliance. Pull claims from the past 12 months for all PSA and DRE billings. Flag any beneficiary who had more than one claim in a 12-month window under a screening indication. Identify whether those claims had clean documentation or whether they were repeat screenings coded incorrectly. |
| 2 | Verify age thresholds at the point of order. Your EHR or practice management system should flag PSA screening orders for male beneficiaries under age 50. If that logic isn't built into your order sets, add it before May 15, 2026. Catching it at the point of order is cheaper than fixing it at the claim denial stage. |
| 3 | Separate screening from diagnostic PSA in your documentation workflow. Train ordering providers on the difference. A screening PSA is ordered on a symptom-free patient with no known risk factors flagging a diagnostic need. A diagnostic PSA has clinical justification beyond routine age-based screening. The ICD-10 code selection needs to reflect that distinction. |
| 4 | Check Medicare Advantage plan policies separately. CMS sets the floor for prostate cancer screening billing guidelines under traditional Medicare. Medicare Advantage plans can add prior authorization requirements, additional documentation criteria, or coverage limits beyond the CMS floor. If you bill Medicare Advantage plans, pull their current policies before May 15, 2026 and compare. |
| 5 | Obtain the specific CPT and HCPCS codes when the full policy publishes. The available policy data does not list specific codes. Monitor the CMS policy page directly — the full text should include applicable procedure codes. Build those codes into your charge description master (CDM) and verify they're mapped correctly in your billing system before the effective date. |
| 6 | Flag any claims in-flight that might be affected. If you have prostate cancer screening claims submitted but not yet adjudicated near the May 15, 2026 effective date, watch for how CMS applies the modified criteria. Denials that weren't happening before the modification date may signal where the change landed. |
| 7 | If your practice volume in prostate cancer screening is high, talk to your compliance officer. This modification affects medical necessity documentation, coding accuracy, and potential exposure on prior claims if the criteria tightened. A compliance officer or billing consultant can help you assess whether a retrospective audit is warranted. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Prostate Cancer Screening Under CMS Policy
A Note on Code Data
The policy data provided for this CMS prostate cancer screening modification does not include specific CPT, HCPCS, or ICD-10 codes. This post will be updated when the full policy text is available with applicable codes.
Billing teams should not assume the absence of listed codes means there are no coding implications. CMS prostate cancer screening billing has historically involved specific procedure codes for PSA testing and digital rectal exams, as well as diagnosis codes distinguishing screening from diagnostic intent. The moment the full policy publishes, verify those codes against your current charge capture.
Do not invent codes based on what you think the policy covers. Pull the source document directly from CMS or from the PayerPolicy policy record at https://app.payerpolicy.org/p/cms/268-v2 once the full text is available.
What to Watch For When Codes Publish
When the full policy text publishes, look specifically for:
- Whether CMS added or removed any CPT codes from covered status
- Whether any codes shifted from covered to non-covered — that's a direct reimbursement hit
- Whether new frequency or age-based coverage conditions were attached to existing codes
- Whether any modifier requirements changed for screening vs. diagnostic PSA claims
These are the four areas where modifications to screening test policies most often create billing exposure. Each one requires a different fix in your charge capture, CDM, or documentation templates.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.